

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中国地利集团
China Dili Group

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1387)

**(1) DECISION OF THE LISTING COMMITTEE ON
CANCELLATION OF LISTING;
(2) REQUEST TO THE LISTING REVIEW COMMITTEE TO REVIEW
DECISION ON CANCELLATION OF LISTING;
AND
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by China Dili Group (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

References are made to the announcements of the Company (i) dated 28 October 2022 in relation to the suspension of trading in all securities of the Company on the Stock Exchange; (ii) dated 28 October 2022 in relation to inside information of the Company; (iii) dated 30 November 2022 in relation to the Initial Resumption Guidance received from the Stock Exchange; (iv) dated 12 December 2022 in relation to the appointment of an independent investigator; (v) dated 27 January 2023 in relation to the quarterly update on resumption progress; (vi) dated 28 March 2023 in relation to the expected delay in publication of annual results for the year ended 31 December 2022 and expected delay in despatch of the 2022 annual report; (vii) dated 14 April 2023 in relation to the Additional Resumption Guidance received from the Stock Exchange and the quarterly update on resumption progress; (viii) dated 27 July 2023 in relation to the quarterly update on resumption progress; (ix) dated 18 August 2023 in relation to the key findings of the Independent Investigation and the appointment of independent internal control consultant; (x) dated 30 August 2023 in relation to the further delay in publication of annual results for the year ended 31 December 2022 and in despatch of the 2022 annual report, expected delay in publication of interim results for the six months ended 30 June 2023 and in despatch of the 2023 interim report, and postponement of the 2023 annual general meeting; (xi) dated 27 October 2023 in relation to the quarterly update on resumption progress; (xii) dated 29 December 2023 in relation to the recent freezing of the Group’s onshore bank deposits; (xiii) dated 9 January 2024 in relation to update on litigation claims; (xiv) dated 9 January 2024 in relation to litigation claims against subsidiaries of the Company; (xv) dated 26 January 2024 in relation to the quarterly update on resumption progress; (xvi) dated 28 March 2024 in relation to the Further Resumption Guidance received from the Stock Exchange; (xvii) dated 28 March 2024 in relation to the further delay in publication of annual results for the year ended 31 December 2022 and interim results for the six months ended 30 June 2023 and in despatch of the 2022 annual report and the 2023 interim report, and expected delay in publication of annual results for the year ended 31 December 2023 and in despatch of the 2023 annual report; (xviii) dated 12 April 2024 in relation to the key findings of the Internal Control Review; and (xix) dated 26 April

2024 in relation to the quarterly update on resumption progress (collectively, the “**Announcements**”). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as defined in the Announcements.

DECISION OF THE LISTING COMMITTEE ON CANCELLATION OF LISTING

The Company received a letter from the Stock Exchange on 17 May 2024 stating that the Listing Committee of the Stock Exchange (the “**Listing Committee**”) has decided to cancel the Company’s listing under Rule 6.01A(1) of the Listing Rules as the Company had not fulfilled the Resumption Guidance (the “**Decision**”).

Under Chapter 2B of the Listing Rules, the Company has the right to have the Decision referred to the Listing Review Committee of the Stock Exchange (the “**Listing Review Committee**”) for review within seven business days from the date of issue of the Decision (i.e. on or before 28 May 2024) (the “**Review**”). If the Company decides not to apply for the Review, the last day of listing of the Company’s shares will be on 31 May 2024 and the listing of its shares will be cancelled with effect from 9:00 a.m. on 3 June 2024.

REVIEW REQUEST OF THE DECISION

On 27 May 2024, the Company submitted an application requesting the Decision be referred to the Listing Review Committee for review pursuant to requirements under Chapter 2B of the Listing Rules.

The Company hereby reminds the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that the outcome of the Review is uncertain. Shareholders who have any queries about the implications of the cancellation of listing of the Company’s shares are advised to seek appropriate professional advice.

Further announcement(s) will be made by the Company in respect thereof as and when appropriate and in accordance with the requirements of the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in all securities of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 28 October 2022, and will remain suspended until further notice.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
China Dili Group
Dai Bin
Executive Director and Chief Executive Officer

Hong Kong, 27 May 2024

As at the date of this announcement, the Board comprises Mr. Dai Bin as executive director; Mr. Yin Jianhong and Mr. Yao Yanzhong as non-executive directors; and Dr. Fan Ren-Da, Anthony, Mr. Wang Yifu, Mr. Leung Chung Ki and Mr. Tang Hon Man as independent non-executive directors.